Melflufen Plus Dexamethasone Safe and Effective For R/R Multiple Myeloma

A large study found GLP-1 drugs don't raise cancer risk; instead, they cut obesity-related cancers by 7% and overall mortality by 8%.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Lurbinectedin plus atezolizumab maintenance significantly improved PFS & OS in extensive-stage SCLC, offering a potential new standard of care.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do support a positive benefit-risk ratio for patients with smoldering multiple myeloma.

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies.